vs
ANI PHARMACEUTICALS INC（ANIP）とMONRO, INC.（MNRO）の財務データ比較。上の社名をクリックして会社を切り替えられます
MONRO, INC.の直近四半期売上が大きい（$293.4M vs $247.1M、ANI PHARMACEUTICALS INCの約1.2倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 3.8%、差は7.3%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs -4.0%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $9.1M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs -2.7%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
モンロー社（Monro, Inc.）は自動車サービス企業で、創業地および本社はアメリカ合衆国ニューヨーク州ロチェスターです。2025年時点で1260店舗を展開しており、店舗数と売上高においてDriven Brandsに次ぐ北米第2位の自動車サービス企業です。
ANIP vs MNRO — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $293.4M |
| 純利益 | $27.5M | $11.1M |
| 粗利率 | — | 34.9% |
| 営業利益率 | 14.1% | 6.3% |
| 純利益率 | 11.1% | 3.8% |
| 売上前年比 | 29.6% | -4.0% |
| 純利益前年比 | 367.5% | 143.1% |
| EPS（希薄化後） | $1.14 | $0.35 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $293.4M | ||
| Q3 25 | $227.8M | $288.9M | ||
| Q2 25 | $211.4M | $301.0M | ||
| Q1 25 | $197.1M | $295.0M | ||
| Q4 24 | $190.6M | $305.8M | ||
| Q3 24 | $148.3M | $301.4M | ||
| Q2 24 | $138.0M | $293.2M | ||
| Q1 24 | $137.4M | $310.1M |
| Q4 25 | $27.5M | $11.1M | ||
| Q3 25 | $26.6M | $5.7M | ||
| Q2 25 | $8.5M | $-8.1M | ||
| Q1 25 | $15.7M | $-21.3M | ||
| Q4 24 | $-10.3M | $4.6M | ||
| Q3 24 | $-24.2M | $5.6M | ||
| Q2 24 | $-2.3M | $5.9M | ||
| Q1 24 | $18.2M | $3.7M |
| Q4 25 | — | 34.9% | ||
| Q3 25 | — | 35.7% | ||
| Q2 25 | — | 35.5% | ||
| Q1 25 | — | 33.0% | ||
| Q4 24 | — | 34.3% | ||
| Q3 24 | — | 35.3% | ||
| Q2 24 | — | 37.2% | ||
| Q1 24 | — | 35.5% |
| Q4 25 | 14.1% | 6.3% | ||
| Q3 25 | 15.9% | 4.4% | ||
| Q2 25 | 6.6% | -2.0% | ||
| Q1 25 | 13.3% | -8.1% | ||
| Q4 24 | -2.3% | 3.3% | ||
| Q3 24 | -13.8% | 4.4% | ||
| Q2 24 | 3.7% | 4.5% | ||
| Q1 24 | 14.8% | 3.3% |
| Q4 25 | 11.1% | 3.8% | ||
| Q3 25 | 11.7% | 2.0% | ||
| Q2 25 | 4.0% | -2.7% | ||
| Q1 25 | 8.0% | -7.2% | ||
| Q4 24 | -5.4% | 1.5% | ||
| Q3 24 | -16.3% | 1.9% | ||
| Q2 24 | -1.7% | 2.0% | ||
| Q1 24 | 13.2% | 1.2% |
| Q4 25 | $1.14 | $0.35 | ||
| Q3 25 | $1.13 | $0.18 | ||
| Q2 25 | $0.36 | $-0.28 | ||
| Q1 25 | $0.69 | $-0.74 | ||
| Q4 24 | $-0.45 | $0.15 | ||
| Q3 24 | $-1.27 | $0.18 | ||
| Q2 24 | $-0.14 | $0.19 | ||
| Q1 24 | $0.82 | $0.12 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $4.9M |
| 総負債低いほど良い | — | $45.0M |
| 株主資本純資産 | $540.7M | $604.9M |
| 総資産 | $1.4B | $1.6B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.07× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $4.9M | ||
| Q3 25 | $262.6M | $10.5M | ||
| Q2 25 | $217.8M | $7.8M | ||
| Q1 25 | $149.8M | $20.8M | ||
| Q4 24 | $144.9M | $10.2M | ||
| Q3 24 | $145.0M | $20.9M | ||
| Q2 24 | $240.1M | $18.7M | ||
| Q1 24 | $228.6M | $6.6M |
| Q4 25 | — | $45.0M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $71.5M | ||
| Q1 25 | — | $61.3M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $62.0M | ||
| Q2 24 | — | $112.0M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $540.7M | $604.9M | ||
| Q3 25 | $505.8M | $601.7M | ||
| Q2 25 | $436.8M | $604.9M | ||
| Q1 25 | $418.6M | $620.8M | ||
| Q4 24 | $403.7M | $648.9M | ||
| Q3 24 | $405.9M | $651.9M | ||
| Q2 24 | $455.8M | $654.4M | ||
| Q1 24 | $452.0M | $656.8M |
| Q4 25 | $1.4B | $1.6B | ||
| Q3 25 | $1.4B | $1.6B | ||
| Q2 25 | $1.3B | $1.6B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.3B | $1.7B | ||
| Q3 24 | $1.3B | $1.7B | ||
| Q2 24 | $920.8M | $1.7B | ||
| Q1 24 | $914.5M | $1.7B |
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.10× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.10× | ||
| Q4 24 | — | 0.09× | ||
| Q3 24 | — | 0.10× | ||
| Q2 24 | — | 0.17× | ||
| Q1 24 | — | 0.16× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $17.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $9.1M |
| FCFマージンFCF / 売上 | 11.8% | 3.1% |
| 設備投資強度設備投資 / 売上 | 0.5% | 3.0% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 1.60× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $49.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $17.8M | ||
| Q3 25 | $44.1M | $32.3M | ||
| Q2 25 | $75.8M | $-1.9M | ||
| Q1 25 | $35.0M | $28.9M | ||
| Q4 24 | $15.9M | $14.8M | ||
| Q3 24 | $12.5M | $62.6M | ||
| Q2 24 | $17.4M | $25.6M | ||
| Q1 24 | $18.3M | $-5.3M |
| Q4 25 | $29.1M | $9.1M | ||
| Q3 25 | $38.0M | $26.6M | ||
| Q2 25 | $71.8M | $-9.3M | ||
| Q1 25 | $32.5M | $23.2M | ||
| Q4 24 | $13.5M | $7.9M | ||
| Q3 24 | $7.7M | $57.6M | ||
| Q2 24 | $13.0M | $16.8M | ||
| Q1 24 | $13.7M | $-11.9M |
| Q4 25 | 11.8% | 3.1% | ||
| Q3 25 | 16.7% | 9.2% | ||
| Q2 25 | 34.0% | -3.1% | ||
| Q1 25 | 16.5% | 7.9% | ||
| Q4 24 | 7.1% | 2.6% | ||
| Q3 24 | 5.2% | 19.1% | ||
| Q2 24 | 9.4% | 5.7% | ||
| Q1 24 | 10.0% | -3.8% |
| Q4 25 | 0.5% | 3.0% | ||
| Q3 25 | 2.7% | 2.0% | ||
| Q2 25 | 1.9% | 2.5% | ||
| Q1 25 | 1.3% | 1.9% | ||
| Q4 24 | 1.3% | 2.2% | ||
| Q3 24 | 3.2% | 1.6% | ||
| Q2 24 | 3.2% | 3.0% | ||
| Q1 24 | 3.3% | 2.1% |
| Q4 25 | 1.10× | 1.60× | ||
| Q3 25 | 1.66× | 5.71× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 3.23× | ||
| Q3 24 | — | 11.08× | ||
| Q2 24 | — | 4.37× | ||
| Q1 24 | 1.00× | -1.42× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
MNRO
| Tires | $150.2M | 51% |
| Maintenance | $73.5M | 25% |
| Brakes | $35.1M | 12% |
| Steering | $24.9M | 8% |
| Batteries | $6.2M | 2% |
| Exhaust | $3.2M | 1% |
